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Abstract: Antidepressant pharmacotherapy is to date the most often used treatment for 
  depression, but the exact mechanism of action underlying its therapeutic effect is still unclear. 
Many theories have been put forward to account for depression, as well as antidepressant   activity, 
but none of them is exhaustive. Neuroimmune endocrine impairment is found in depressed 
patients; high levels of circulating corticosteroids along with hyperactivation of the immune 
system, high levels of proinflammatory cytokines, low levels of melatonin in plasma and urine, 
and disentrainment of circadian rhythms have been demonstrated. Moreover,   antidepressant 
treatment seems to correct or at least to interfere with these alterations. In this review, we 
summarize the complex neuroimmune endocrine and chronobiological alterations found in 
patients with depression and how these systems interact with each other. We also explain how 
antidepressant therapy can modify these systems, along with some possible mechanisms of 
action shown in animal and human models.
Keywords: antidepressant agents, biological markers, human, cytokines, neuroinflammation, 
psychoneuroimmunology, endophenotype
Introduction
Major depressive disorder is a widespread illness of great socioeconomic impact, 
and according to the World Hesalth Organization, will be the second leading cause 
of   disability in terms of burden disease in the future. A US epidemiological study 
reports depression to have a lifetime prevalence of 16.2%.1 Possible therapeutic 
strategies involve social, psychological, and pharmacological treatments. Current 
pharmacotherapy is associated with a 55%–70% lack of responsiveness in treated 
subjects, being also associated with a delayed onset of action of several weeks and 
important side effects. Therefore, there is a need for further investigation of possible 
treatments for depression. Immune endocrine disturbances have been shown to play a 
role in the pathophysiology of depression and to be restored by effective antidepressant 
treatment.2–7 Thus, agents which correct the neuroimmune endocrine imbalance have 
been proposed as potential novel therapeutics for depression. In this review, we will 
discuss the main mechanisms that support the hypothesis that antidepressants exert 
their therapeutic benefit by correcting immune and endocrine disturbances.
Neuroendocrine disturbances in depressed patients
Melatonin
Abnormalities in neuroendocrine regulation are widespread in depressive illness. 
One of the focuses of research in depressed patients has been melatonin, a naturally 
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  occurring “lights off” hormone. Melatonin is released accord-
ing to a daily rhythm, depending on the prevailing light/dark 
phase of the day.8 Although many organs are now shown to 
produce it, the diurnal rhythm of melatonin in the blood is 
exclusively driven by its secretion from the pineal gland.9 
Temporal organization in humans presents a daily adjustment 
to the environmental light/dark cycle; during the night, the 
master circadian clock in the suprachiasmatic nuclei of the 
hypothalamus stimulates the pineal gland via a polysynaptic 
noradrenergic pathway.10 This gland produces and releases 
the nocturnal hormone, melatonin, which circulates through-
out the body and adjusts several bodily functions   according to 
the existence and duration of darkness. During the day, envi-
ronmental light detected by the retina adjusts the central clock 
in the suprachiasmatic nuclei, ie, melanopsin-  containing 
ganglion cells send stimulatory glutamatergic signals to 
the suprachiasmatic nuclei that modulate the expression of 
specific clock genes suppressing the stimulation of the pineal 
gland.11 This modulation will lead, in turn, to a reduction of 
circulating melatonin.12,13 Suprachiasmatic nuclei neurons 
also receive afferent serotonergic projections from the raphe 
nuclei14,15 which exert inhibitory control over the suprachias-
matic nuclei neuronal response to light.16,17 Melatonin synthe-
sis is a multistage process that happens inside pinealocytes, 
which are the functional cells of the pineal gland. Melatonin 
is synthesized from tryptophan, which is hydroxylated by 
tryptophan hydroxylase, then decarboxylated into sero-
tonin, transformed into N-acetylserotonin by arylalkylamine 
N-acetyltransferase (AANAT), which is the reported rate-
limiting melatonin synthesis enzyme, and finally transformed 
into melatonin by acetyl serotonin-O-methyltransferase. 
Norepinephrine binds β1 adrenergic receptors from the mem-
brane of the   pinealocytes; these, through G protein adenylate 
cyclase, increase cytosolic cyclic adenosine monophosphate 
(cAMP), which stimulates the nuclear synthesis of AANAT 
and increases the rate of transformation of serotonin into 
melatonin.18 Due to its   regulation, it has been suggested 
that melatonin could be used as a readout of noradrenergic 
function after   antidepressant administration.19,20 Moreover, to 
support the idea that   melatonin synthesis is regulated by light 
and day cycles, expression of tryptophan-hydroxylase mRNA 
and the activity of the enzyme have been analyzed during the 
day; peak levels of both occur at night, which is when we can 
measure the highest level of circulating melatonin.21
Melatonin is excreted from pinealocytes into the 
  circulatory system where it exerts a wide range of activi-
ties (Figure 1), ie, regulating circadian rhythms and sleep,22 
promoting neurogenesis,23 modulating the immune system, 
improving defenses and/or decreasing inflammation,24–27 and 
regulating metabolism,28 especially in lipids.29 It also has 
very strong antioxidant and oncostatic effects,30–32 and most 
of these functions are exerted through the G protein-coupled 
membrane receptors, MT1 and MT2.18
What happens to depressed patients? Many studies have 
been done so far investigating melatonin impairment in 
depression, and have focused mainly on circadian melatonin 
rhythm profiles, plasma melatonin, urinary 6-sulphatoxime-
latonin (aMT6s), the main melatonin metabolite, and the 
expression of enzymes implicated in melatonin synthesis.
There are reports showing lower plasma melatonin levels 
in depressed patients compared with controls.33–35 There are 
also some hints that maximum nocturnal plasma melatonin 
levels are lower in patients with major unipolar or bipolar 
depression in the coexistence of an abnormal dexamethasone 
suppression test (DST) compared with controls and patients 
with a normal DST. The intensity of depression is negatively 
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Figure 1 Schematic representation of the main effects exerted by melatonin.
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correlated with maximum nocturnal plasma melatonin 
levels,34,36 as well as sensitivity of pineal β-adrenoceptors. 
As shown in a study of depressed patients that correlated 
overnight urinary melatonin before and after administration 
of atenolol, a β-adrenoceptor antagonist, the greater the 
decrease in melatonin after atenolol, the more severe the 
depression.35 Moreover, the duration in hours that melatonin 
was present in the plasma correlates with depressive symp-
tomatology.37 Some studies focusing on the melancholic 
subtype of depression found a smaller rise in melatonin 
and lower serum melatonin   compared with controls,38,39 
while postpartum depression was related to higher plasma 
melatonin levels.33   Furthermore, a history of depression 
was related to melatonin impairment,33 and postmenopausal 
women showed a longer duration of aMT6s excretion if they 
had a family history of   depression, as well as delayed offset 
of aMT6 excretion with current major depression and a later 
nocturnal peak with both   current and past depression.40 We 
still do not know the exact mechanism by which melatonin 
impairment occurs in patients with depression, but studies 
in animals have given us some hints, ie, administration of 
melatonin seemed to have antidepressant efficacy in mice, 
preventing changes in behavior, coat state, and an increase 
in cortisol levels when they were subjected to unpredictable 
stressors.41 Moreover, the melatonin receptor, MT1 has been 
investigated, and MT1 knockout mice showed an increased 
immobility time in the forced swim test (a depressive-like 
behavior) compared with wild-type mice.42 MT1 receptors 
are widespread in the human hypothalamus and in some 
parts of the pituitary gland, as well as in the pineal gland, 
and are   colocalized in some corticotropin-releasing hormone 
neurons.43 These areas are implicated in neuroendocrine 
modulation and in the regulation of the circadian system,44 
suggesting again that melatonin can be involved in the 
pathogenesis of the neuroendocrine impairment found in 
depressed patients. Recent research has attempted to inves-
tigate deeper into the biological   mechanisms that lie behind 
melatonin impairment in   depression. A study conducted in 
2010 undertook a genetic investigation in 181 patients with 
recurrent depression and 149 controls. The investigators 
analyzed for the presence of two different single nucleotide 
polymorphisms, rs4446909 and rs5989681, in the promoter 
B region of the acetylserotonin methyltransferase (ASMT) 
enzyme for melatonin synthesis, and found three different 
genotype forms for each of these single nucleotide poly-
morphisms, ie, rs4446909 was present in AA, AG, and GG 
form, and rs5989681 instead was present in CC, GC, and 
GG forms. They showed that the AA type (for rs4446909)   
and the GG type (for the rs5989681) led to increased 
  expression of the enzymes compared with the other geno-
types and, interestingly, that they were both associated with 
a decreased risk of having recurrent   depression.   Moreover, it 
was shown that depressed patients had significant decreased 
ATMS expression compared with the controls.45 These stud-
ies, taken together, point even more to the involvement of 
melatonin in the pathogenesis of depression.
Circadian rhythms
Depressed patients have shown abnormalities in many 
  circadian systems, including sleep/wake cycles, with 
  generally early morning waking, changes in sleep architecture 
with shortened rapid eye movement latency, and the rapid eye 
movement-sleep phase advanced to the first third of the sleep 
cycle, as well as diurnal mood changes, seasonal changes, 
variation in the temperature nadir time, peak cortisol levels, 
and time of melatonin onset.3,46 Circadian impairments have 
been hypothesized to be involved in the development of 
seasonal affective disorder;47 specifically phase shift theories 
have been proposed, and light therapy has proven its   efficacy 
in both seasonal and nonseasonal affective   disorders.48 
Understanding the basis of circadian biology is the key to 
explain those alterations. How does our body create and 
regulate circadian rhythms? Regulatory centers, such as the 
suprachiasmatic nucleus, contain the so-called “clock cells” 
with active clock genes in the nucleus. These cells, through 
autoregulatory transcription-(post)translational feedback 
loops, generate electric impulses in the form of synchronized 
neuronal signals toward sympathetic and parasympathetic 
nuclei. The latter send nerve connections to many organs, 
regulating adrenal corticosteroid excretion, amongst other 
processes. These hormones, in turn, regulate the circadian 
rhythm with a negative feedback by resetting the time of 
the clock cells.49 Clock genes are found also in the adrenal 
glands, and mutations in these can alter daily corticosteroid 
excretion.50 In 1985, Linkowski et al found early timing of 
adrenocorticotropic hormone (ACTH) cortisol secretion, as 
well as higher mean plasma cortisol levels, in 18 depressed 
patients (eight unipolar and 10 bipolar) compared with eight 
controls.51 Another study compared biological variables, 
such as core body temperature, cortisol, norepinephrine, 
thyroid-stimulating hormone, and melatonin, in three groups 
of patients with major affective disorder, ie, 16 depressed 
patients, 15 depressed patients who recovered after 3 weeks of 
antidepressant treatment, and 16 controls. They found higher 
levels of cortisol and lower levels of nocturnal melatonin 
in depressed patients than in the controls.52 Moreover, they 
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found a negative correlation between the amplitude of circa-
dian rhythms and Hamilton depression scores, ie, the lower 
the amplitude, the more severe the depression, and recovery 
was associated with reversal of circadian   impairment. Clock 
genes can also be modulated by different hormones; ACTH 
is known to increase PER1 (period 1) mRNA in the adrenal 
glands, stimulating the excretion of cortisol, while melatonin 
itself can dampen these ACTH-correlated effects, as shown 
by a recent study.53 This mechanism may partially explain the 
previously elicited alterations found in depressed patients. 
Since melatonin is known to be low in these patients, cortisol 
levels may be high because of this lack of inhibitory mela-
tonin effect. Another characteristic of depression is the asso-
ciation of severity of the illness with phase angles of different 
circadian variables, such as dim light melatonin onset and the 
average midpoint of sleep,54 dim light melatonin onset and 
core body temperature,55 and dim light melatonin onset and 
cortisol acrophase (the 24-hour peak).55 Other circadian 
abnormalities found in depressed patients were a tendency 
toward eveningness, a later sleep onset and midpoints, and 
a delayed dim light melatonin onset.55 These findings high-
light the presence of neuroendocrine abnormalities, such as 
circadian misalignments, in depressed patients.56
HPA axis and glucocorticoid receptors
In addition to the melatonergic and circadian disturbances 
found in major depression, clinical studies have also dem-
onstrated impairments in the hypothalamo-pituitary-adrenal 
(HPA) axis. Glucocorticoids are secreted by the adrenal gland 
through a neuroendocrine pathway, ie, the hypothalamus 
stimulates the pituitary gland via corticotropin-releasing 
hormone (CRH) which in turn stimulates the adrenal gland 
to release glucocorticoids via ACTH. The main function of 
these steroid hormones is to regulate energy metabolism, 
thereby increasing gluconeogenesis, lipolysis, and protein 
degradation. These hormones also have a crucial anti-
inflammatory action.57 They exert many other functions, 
like inducing behavioral adaptations in stressful situations; 
when exposed to environmental, psychological, or biological 
stressors, our bodies produce cortisol, which causes adap-
tive behavior, like focused attention, alertness, and immune 
system suppression.57 In addition, cortisol has been shown 
to regulate memory, emotional appraisal of events, neuro-
genesis, and neuronal survival (Figure 2).58
Glucocorticoids exert their function through the 
  glucocorticoid receptor (GR) and the mineralocorticoid 
receptor.59 These are widespread in body tissues, but   particular 
attention has been focused on the ones implicated in the nega-
tive feedback regulation of the HPA axis. These are found in 
the paraventricular nucleus of the hypothalamus, in the CRH/
vasopressin neurons of the anterior pituitary, and in the hip-
pocampus and upstream regulator of the HPA axis, as well as 
in other areas of the brain.60,61 The HPA axis is regulated also 
by biological stimuli, such as proinflammatory cytokines, ie, 
interleukin (IL)-1 and IL-6,62,63 and psychologically stress-
ful situations.64 A huge number of findings show that many 
depressed patients (up to 80% when severely depressed) are 
shown to have hyperactivation of the HPA axis, impairment 
comparable with a sustained stress response, in the absence of 
a stressor.65–69 High cortisol levels in the cerebrospinal fluid, 
plasma, and urine,70 impairment in the negative feedback 
regulation of the HPA axis,68,71 and hyperplasia of the adrenal 
and pituitary glands are also found in depressed patients.72,73 
GR-mediated negative feedback has been widely investigated 
using specific tests which demonstrated nonsuppression of 
cortisol secretion following administration of a synthetic 
DST; dexamethasone pretreatment also showed a lack of the 
inhibition of ACTH responses to CRH expected in healthy 
Immune suppression 
Neurogenesis 
Energetic metabolism (↑energetic substrates) 
Behavioral, mnemonic and 
emotional adaptation to stress
Neuronal survival  
Glucocorticoids
Figure 2 Schematic representation of the main effects exerted by glucocorticoids.
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subjects (dexamethasone/CRH test).68,74 While DST and the 
dexamethasone/CRH test suggest impaired feedback inhibi-
tion at the level of the pituitary,59 impaired responsiveness to 
hydrocortisone challenge in depressed patients may represent 
feedback alterations in the brain,75 although this latter finding 
is inconsistent.76 Furthermore, DST and dexamethasone/CRH 
tests are a biomarker of treatment success; resolution of distur-
bances in negative feedback in patients who are nonsuppressors 
before treatment is associated with efficacious antidepressant 
treatment, with up to 75% of nonsuppressor patients switching 
to suppressor status coincident with a treatment response.77,78
Furthermore, another analysis of HPA reactivity to stress is 
the so-called “cortisol awakening response” measured in sali-
vary cortisol samples taken after awaking. Depressed patients 
with current or remitted depression show a higher cortisol 
awakening response compared with controls, and this has 
been suggested to be indicative of increased biological vulner-
ability to depression.79 Studies conducted so far (as reviewed 
elsewhere)80,81 have shown that the noradrenergic system exerts 
an inhibitory action on the HPA axis, decreasing the release 
of ACTH, probably through α-1 receptors. Moreover, it has 
been found that normal diurnal fluctuation of the activity of 
the adrenal cortex requires integrity of the serotonergic system, 
particularly referring to the suprachiasmatic nucleus, anterior 
hypothalamus, and limbic system. Because these two systems 
are impaired in depressed patients, as shown by norepinephrine 
and serotonin abnormalities,5 it is possible that these neurologi-
cal alterations can contribute to the endocrine impairments we 
have spoken of so far. This connection between noradrenergic 
and serotonergic impairment and HPA axis activity suggests 
a possible link between monoamines and the neuroendocrine 
abnormalities found in depressed patients.
Pineal-HPA axis
There is evidence of reciprocal interference between melatonin 
and cortisol, but it is not yet known if this cross talk is directly 
involved in the neuroendocrine impairment found in depressed 
patients. Studies conducted in animals give us some clues, in 
that rats show hypertrophy of the adrenal and pituitary glands 
following pinealectomy.82,83 Also, under acute or chronic stress, 
they show a decreased adrenocortical response when treated 
chronically with melatonin, compared with controls. Moreover, 
melatonin-treated rats have an increase in HPA axis sensitivity 
to the glucocorticoid suppression test.84 These findings suggest 
that there is a modulatory role of melatonin on HPA axis activ-
ity and a positive effect in restoring negative glucocorticoid 
feedback, in particular when the animal is under stress. One 
study of the neuroendocrine effects of agomelatine, a new 
antidepressant, compared with melatonin in transgenic rats 
with impaired GR found that melatonin increased GR mRNA 
expression in the dentate gyrus, compared with wild-type 
animals.85 Moreover, it was found that melatonin had an inhibi-
tory action on GR function in mouse thymocytes, in particular 
reducing GR receptor nuclear translocation.86 Furthermore, 
rats treated with corticosterone showed a two-fold increase in 
nocturnal melatonin in vivo, and extracted pineal glands from 
treated rats showed a significant increase in melatonin enzyme 
activity compared with controls.87,88 A possible pathway was 
shown in a study89 where isolated pineal glands from rats were 
cultured with three different substances, ie, ALLN, a protea-
some inhibitor, an antagonist of the nuclear factor κB (NF-κB), 
or corticosterone, with or without a GR antagonist, all before 
stimulation with norepinephrine. As shown in   Figure 3, corti-
costerone increased the norepinephrine-mediated elevation of 
melatonin and N-acetylserotonin, and this effect was inhibited 
Glucocorticoid 
GR
NF-κB
NF-κB
Proteasome
I-κB 
Nucleus
Pinealocyte
cAMP
PKA
Melatonin  
synthesis 
Decrease
Increase
Glucocorticoid 
inhibitory effect 
NE
Melatonin
Figure 3 Schematic representation of intracellular interaction between glucocorticoid and melatonin.
Abbreviations: GR, glucocorticoid receptor; NE, norepinephrine.
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by GR antagonists; the potentiating effect of corticosteroids was 
then mimicked by treatment with an NF-κB antagonist as well 
as with ALLN. Physiologically, proteasomes are necessary for 
the translocation of NF-κB into the nucleus since they degrade 
inhibitory factors (I-kB) which keep NF-κB bound to the cyto-
sol. These results show a clear pathway by which corticosterone 
increases melatonin production through inhibition of nuclear 
translocation of NF-κB.
Accordingly, one placebo-controlled study conducted 
in 12 blind human subjects analyzed the effect of a single 
dose of melatonin on neuroendocrine parameters of sleep 
and found that melatonin could alter nocturnal cortisol 
and ACTH levels depending on the period of sleep. In the 
first half, ACTH was higher than placebo and even higher 
in the second half, while cortisol levels were lower in the 
first half and increased in the second half.90 In summary, it 
seems that melatonin has an inhibitory action on adrenal 
and pituitary volume and a positive action on GR expression 
in the brain, thus increasing HPA negative feedback. On 
the other hand, glucocorticoids have a positive modulating 
effect on melatonin production. The pineal gland, express-
ing the GR, seems to monitor glucocorticoid levels and 
control their excessive elevation, as happens under stress 
conditions. This cross talk suggests that neuroendocrine 
impairments may work together in the development of the 
whole constellation of neurobiological alterations found 
in depression.
Melatonin and the inflammatory 
system
In the past ten years, an increasing amount of evidence sug-
gests that activation of the inflammatory system is involved 
in the pathogenesis of depression. Firstly, depressed patients 
have high levels of cytokines, with increased levels of IL-6 
being the most frequently observed,91–95 and an elevation 
in IL-1-β and tumor necrosis factor alpha has also been 
reported.96–99 Furthermore, major depression is strongly 
associated with increased levels of acute phase proteins, 
including C-reactive protein.100,101 Inflammatory markers 
not only increase the risk for depression and correlate 
positively with severity of depressive symptoms102 but also 
modulate responsiveness to antidepressants.103,104 Secondly, 
clinical administration of cytokines or agents which increase 
production of proinflammatory cytokines can induce depres-
sive symptoms in patients with no previous mental health 
issues,105–107 while inflammatory-induced depression can 
also be treated with antidepressants.108 Thirdly, activation 
of the immune system and administration of proinflam-
matory cytokines to laboratory animals induces behavior 
that is similar to depression in humans.109 Activation of the 
inflammatory system and cytokine secretion is one possible 
mechanism that could bring about neuroendocrine abnor-
malities in depression.
Cytokines are a large and diverse family of small signal 
molecules, best known for their immunomodulatory effect, 
resulting in production of other cytokines (chemotaxis) 
and an increase in the number of surface receptors for 
other molecules, activation of leukocytes, or suppression of 
their own effect. The most prevalent group of cytokines is 
composed of various subtypes of interleukins; while some 
stimulate immune cell proliferation and differentiation, 
others are predominantly inhibitory. One functional group 
of proinflammatory cytokines includes tumor necrosis fac-
tor alpha, IL-1, IL-6, and type I interferon-α/β. Cytokines 
can activate the HPA axis, causing an elevation in systemic 
glucocorticoid levels and inhibiting GR function at multiple 
levels, including GR translocation and induction of GR 
isoforms with a reduced capacity to bind ligand.110,111 IL-6 
has been reported to induce a prolonged increase in plasma 
concentrations of ACTH and cortisol in healthy men.112 A 
number of studies have demonstrated that treatment with 
proinflammatory cytokines induces a decrease in GR func-
tion, as shown by lower sensitivity to the effects of gluco-
corticoids on functional endpoints and decreased GR affinity 
for ligand. Moreover, studies performed in peripheral cells 
and tissues of patients with inflammatory diseases such as 
asthma, ulcerative colitis, acquired immunodeficiency syn-
drome, and rheumatoid arthritis, especially those showing 
resistance to the therapeutic effects of glucocorticoids, have 
also demonstrated reductions in GR function and affinity 
that are similar to those induced by cytokines.106,113 Indeed, 
major depression has also been associated with evidence of 
immune inflammation and increased levels of proinflamma-
tory cytokines. It has been shown that the proinflammatory 
cytokine IL-1 directly blocks GR translocation and func-
tion in vitro,106 an effect that is virtually opposite to that of 
antidepressants in the same experimental system.114,115 These 
experiments have shown that the effects of IL-1 are medi-
ated by stimulating p38 mitogen-activated protein kinase 
signal transduction.
Apart from the HPA axis, neuroimmune endocrine 
interactions also involve the pineal gland, which influ-
ences the development and function of the immune system, 
while membrane-bound melatonin receptors are found in 
lymphoid glands and immune cells.116,117 In addition to 
mediating immune reactions and GR function, cytokines 
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have been shown to alter sleep architecture significantly.112 
Inflammatory agents can also regulate melatonin synthesis. 
It is known that tumor necrosis factor leads to inhibition of 
AANAT transcription and production of N-acetylserotonin 
and melatonin in cultured glands. Furthermore, pinealocytes 
express receptors for lipopolysaccharide, which can trig-
ger the NF-κB pathway and inhibit melatonin synthesis. 
Negative modulation of norepinephrine-induced melatonin 
production by tumor necrosis factor alpha is a transient 
phenomenon in the sequence of the inflammatory response, 
while a self-  regulatory response in the pineal gland would 
allow restoration of the nocturnal melatonin surge.118 This 
regulatory mechanism is disrupted when very high systemic 
tumor necrosis factor alpha levels are present, resulting in 
abnormalities in the secretion of circadian melatonin, mainly 
related to an absence of the diurnal rhythm. Therefore, the 
melatonin cycle impairment reported in depression40,55,56,119 
may occur at the onset of an inflammatory response.  AANAT 
is considered to play a key role in the regulation of melatonin 
biosynthesis because changes in its activity are paralleled by 
alterations in melatonin levels.120 The interaction of endog-
enous norepinephrine with β-adrenoceptors has been sug-
gested to increase AANAT activity and melatonin release.121 
β-adrenoceptor stimulation has been shown to increase gene 
expression and protein production of tumor necrosis factor 
alpha as well as IL-1β and IL-6.122 However, the available 
data suggest that enhanced adrenergic tonus leads to immu-
nosuppression, primarily via alpha 2-receptor-mediated 
mechanisms.123 Consequently, chronic β-receptor blockade 
reduces plasma levels of IL-6.124 Also, stress-induced activa-
tion of NF-κB in peripheral blood mononuclear cells appears 
to be dependent on norepinephrine and can be brought 
down by α1-adrenoceptor blockade.125 It has been reported 
that mice kept under constant light or receiving injections 
of β-adrenergic blockers (propranolol) to inhibit melatonin 
synthesis had an inability to mount a primary antibody 
response to sheep red blood cells, decreased cellularity in 
the thymus and spleen, and a depressed autologous mixed 
lymphocyte reaction. All of these effects were reversed by 
melatonin administration when given in the late afternoon.126 
β-adrenoceptor blockers, which depress melatonin secretion, 
exert immunosuppressive effects only when given in the 
evening,35 when the immunoenhancing effect of melatonin is 
highest. Exogenous melatonin reverses beta-blocker-induced 
immunosuppression and enhances immune parameters.
Melatonin on the one hand promotes inflammation but 
on the other counteracts it. These effects can in fact be 
dependent on the interaction between melatonin and NF-κB; 
the hormone has been reported to inhibit NF-κB in vari-
ous animal models.127,128 As a matter of fact, melatonin is 
also able to activate NF-κB, thus regulating the expression 
of adhesion molecules on circulating leukocytes.129,130 NF-κB, 
a determinant of inflammatory responses, is constitutively 
expressed in the pineal gland, which possesses receptors to 
trigger the NF-κB pathway.118 Activation of NF-κB exag-
gerates the inflammatory response including the release of 
the proinflammatory cytokines, tumor necrosis factor alpha, 
IL-1, and IL-6, while inhibition of pineal NF-κB leads to 
enhancement of melatonin production.118 In turn, melatonin 
inhibits translocation of NF-κB to the nucleus128 and inflam-
mation mediated by NF-κB. It has been suggested that NF-κB 
inhibition can be achieved through activation of transcription 
factor Nrf2 which protects cells and tissues from oxidative 
stress by activating protective antioxidants and detoxifying 
enzymes. Reports that Nrf2 disruptions are associated with 
increased NF-κB further support this hypothesis.131,132 The 
mechanism mentioned above further expands and integrates 
the concept of melatonin being a powerful antioxidant with 
anti-inflammatory properties.
In addition, not only cytokines but also glucocorticoids 
transmit signals through a common NF-κB pathway to induce 
and turn off inflammatory responses, respectively,133 which 
suggests an even more profound effect of melatonin on the 
inflammatory response. Melatonin has been shown to abol-
ish several effects of exogenous corticoids inducing immune 
depression,126 and is believed to work as an antiadrenocortical 
or antistress factor.84 The melatonin/corticoid relationship 
is significant because high absolute levels of corticoids and 
disorganization of the normal rhythm of corticoid release are 
also involved in the pathogenesis of depression. In line with 
these findings, melatonin acts against the negative effects of 
stress on immune homeostasis; characteristics such as sleep 
duration can also entail variations in inflammatory mark-
ers. There is also evidence of elevated levels of IL-6 and 
C-reactive protein in short sleeping women.134 Moreover, 
patients with major depression show abnormal IL-6 pro-
duction across the melatonin cycle,93 indicating a possible 
modulating effect of melatonin on the immune system. In 
line with this, humoral and cellular immunities are signifi-
cantly influenced by melatonin,135 through specific receptors, 
MT1/MT2, and high affinity nuclear receptors (RZR) found 
on leukocytes. Furthermore, the last can synthesize mela-
tonin, having the enzyme necessary for its production.136 
Gender, age, the effects of maturation or activation on the 
immune system, and stressful conditions are all factors 
influencing the effects of melatonin on the immune system,137   
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which from one side promotes and from the other counteracts 
inflammation simultaneously because of its differential proin-
flammatory and anti-inflammatory roles.136 Pineal activity 
induces feedback of an inflammatory response, and factors 
secreted by activated immune cells act as messages which 
are understood by the pineal gland, closing the regulatory 
loop of the immune-pineal axis.
Another main pathway by which cytokines can induce 
neuroendocrine abnormalities in depression involves 
  tryptophan metabolism. Tryptophan either leads to the 
synthesis of serotonin and melatonin or to the kynurenine 
pathway.   Tryptophan via indoleamine-2,3-dioxygenase is 
converted into kynurenine, which in turn can take two differ-
ent pathways, ie, one leading to a neuroprotective metabolite, 
kynurenic acid, and the other through kynurene-3-mono-
oxygenase to neurotoxic metabolites (3-hydroxykynurenine 
and then quinolinic acid).6 Proinflammatory cytokines have 
a positive effect on kynurene-3-mono-oxygenase, shifting 
tryptophan metabolism towards a neurotoxic pathway.138–140 
External or psychosocial factors as well as internal inflam-
matory conditions may trigger depression through an inflam-
matory process.141 Furthermore, lipopolysaccharide-treated 
mice show depressive-like behavior that was prevented by 
administration of anti-inflammatory drugs which attenuated 
cytokine expression induced by lipopolysaccharide or directly 
by a kynurene-3-mono-oxygenase antagonist. Those treat-
ments also normalized the kynurenine/tryptophan ratio, while 
direct administration of kynurenine induced depressive-like 
behavior in healthy mice.142 These results reinforce the idea 
that kynurene-3-mono-oxygenase is a central enzyme in the 
development of depressive-like behavior induced by inflam-
mation. All these findings taken together contribute to the idea 
that depression is the symptomatic manifestation of a multi-
factorial disease which involves, in addition to well known 
psychological and social factors, underlying abnormalities in 
the complex web of neuroendocrine pathways and possibly 
the intercommunications between all these systems.
Therapeutic actions  
of antidepressants
How do antidepressants exert their therapeutic action? 
Although the exact etiopathogenesis of depression is not 
clear, pharmacotherapy has to date targeted and modulated 
various sites of action believed to be impaired in this major 
disease, ie, monoamine levels, serotonin transporter, receptor 
abnormalities, neuropeptide systems, glutamatergic neu-
rotransmission, HPA axis, and circadian rhythm misalign-
ment.143 In this section, we focus attention on the   possible 
effects of antidepressants on the main neuroendocrine 
abnormalities found in depression, in particular melatonin, 
cortisol, and immune system impairment.
Effects on melatonin
The effects of antidepressant medication on melatonin 
synthesis, metabolism, and circulating levels have been 
extensively studied. Almost every class of antidepressant 
has been tested, ie, tricyclic antidepressants, tetracyclic 
antidepressants, monoamine oxidase inhibitors, serotonin-
norepinephrine reuptake inhibitors, and selective serotonin 
reuptake inhibitors.
Studies on isolated rat pineal glands incubated with desip-
ramine (a tricyclic antidepressant) showed increased levels 
of melatonin and increased activity of N-acetyltransferase 
compared with controls.144,145 A similar effect was found 
with venlafaxine (a serotonin-norepinephrine reuptake 
inhibitor) on acute treatment.146 However, melatonin levels 
were attenuated by subchronic treatment, possibly because of 
adaptive desensitization of the pinealocyte β-adrenoceptors 
that maintain normal pineal function after modification of 
overall pineal synaptic function.145,146 Another study showed 
that fluoxetine (a selective serotonin reuptake inhibitor) had a 
positive effect on AA-NAT gene expression in the hippocam-
pus and striatum, indicating a possible pathway via antide-
pressants which modulate melatonin synthesis.147 Moreover, 
fluvoxamine (a selective serotonin reuptake inhibitor) seems 
to have an inhibitory effect on hepatic cytochrome peroxidase 
(CYP450), which is implicated in melatonin catabolism,148,149 
but this was not confirmed by other antidepressants, except 
for paroxetine, a selective serotonin reuptake inhibitor, 
given to supratherapeutic concentrations. Another possible 
target of selective serotonin reuptake inhibitors seems to be 
hepatic tryptophan pyrrolase (the main enzyme degrading 
tryptophan), that paroxetine has been shown to inhibit150 
which, in turn, can increase circulating tryptophan levels, 
leading indirectly to an increase in the pineal substrate for 
melatonin synthesis.
Studies in depressed patients seem to confirm the idea 
that antidepressants modulate melatonin (Table 1). A large 
number have tested desipramine and consistently found that 
it increases circulating melatonin levels and urinary aMT6s 
concentrations after treatment compared with controls after 
one day,20 one week,151,152 3 weeks,153 and 6 weeks.20 Interest-
ingly, one study found that long-term treatment (6 weeks) led 
to normalization of urinary aMT6s after an initial increase in 
the short term. This normalization can be explained again by 
an adaptive mechanism on the part of β1-adrenoceptors in 
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the pineal gland to the constant high levels of norepinephrine 
in the synaptic cleft.152 Similar results were found following 
3–6 weeks of treatment with a monoamine oxidase inhibitor, 
tranylcypromine or clorgyline, with regard to urinary aMT6s 
in 27 depressed patients.154 These findings were confirmed 
also for mirtazapine (a tetracyclic antidepressant) given in the 
long term.155 Furthermore, a recent study by Carvalho et al 
showed an increase in melatonin production after treatment 
with fluoxetine and duloxetine, a serotonin-norepinephrine 
reuptake inhibitor, in drug-free depressed patients compared 
with placebo; both groups had the same improvement in 
emotional state, suggesting a pharmacological effect of 
antidepressants on melatonin which may not be directly 
related to their therapeutic action.156 In contrast with those 
findings, another study157 measured plasma melatonin before 
and after 8 weeks of treatment with clomipramine (a tricyclic 
  antidepressant) in 20 depressed patients compared with 14 
healthy subjects. Surprisingly, they showed that depressed 
patients had higher levels of both diurnal and nocturnal mela-
tonin compared with controls. Further, like previous studies, 
they showed that clomipramine significantly increased diur-
nal melatonin but controversially decreased nocturnal secre-
tion; however, this latter finding was not significant. Finally, 
pineal reactivity to antidepressants seems to be a potential 
biomarker of patient response to treatment, as shown by a 
study in 24 depressed outpatients treated with either the 
selective serotonin reuptake inhibitor, fluvoxamine, or the 
tricyclic antidepressant, imipramine, for 6 weeks. When 
measuring urinary aMT6s, the results divided responders 
into those who showed an increase in the metabolite and 
nonresponders who showed a decrease.158
Similar results were found observing melatonin   modulation 
by antidepressants given to healthy subjects (Table 2). Two 
interesting studies investigated the effect of desipramine 
in the short and long term and shed some light on the pos-
sible mechanisms of interaction between antidepressants 
and   melatonin. Desipramine19 induced an initial increase in 
plasma melatonin during the first week of treatment, while 
for the other days it caused a progressive decrease until it 
reached normal levels again. Moreover, there was a rebound 
effect after treatment withdrawal. The authors suggested that 
desipramine caused adaptive inhibition of the presynaptic 
junction firing rate leading to a desensitization of presynaptic 
a2-adrenoceptors implicated in the control of the negative 
feedback on the presynaptic portion; when desipramine is 
withdrawn, there is an increased firing rate at the prejunctional 
synapses, which, in the presence of reduced negative feedback, 
leads to increased norepinephrine outflow, and thus in plasma 
melatonin secretion.19 A second study indicates that the effect 
of desipramine on melatonin is due more to increased norepi-
nephrine availability at the synaptic   junction induced by the 
antidepressant than to other effects on melatonin metabolism. 
Table 1 Antidepressant effect on melatonin in depressed patients
Reference Antidepressant Treatment Plasma melatonin Urinary 6-sulphatoximelatonin
Thompson et al153 Desipramine 3 weeks ↑
Golden et al154 Tranylcypromine 
Clorgyline 
Desipramine
3–6 weeks ↑ 
↑ 
↑
Bearn et al151 Desipramine 1 day 
1 week 
2 weeks 
3 weeks
= 
↑ 
↑ 
↑
Kennedy and Brown152 Desipramine 1 week 
6 weeks
↑ 
=
Palazidou et al161 Desipramine After 1 day 
Six weeks
↑ 
↑
Brown38 Desipramine 5 weeks ↑
Rabe-Jabłońska and Szymanska157 Clomipramine 8 weeks ↓
Miller et al158 Fluvoxamine 
imipramine
6 weeks 
6 weeks
↑ in responders 
↓ in nonresponders 
↑ in responders 
↓ in nonresponders
Schmid et al155 Mirtazapine Long-term (28 days) ↑
Carvalho and Pariante4 Fluoxetine 
Duloxetine
8 weeks  = 
↑ 
↑ 
↑
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Eight male volunteers administered desipramine at 4 pm 
showed an increase in plasma melatonin at 9 pm, 10 pm, 11 
pm, and midnight and an increase in nocturnal aMT6s at 11 
pm and midnight, but no significant effect on total aMT6s in 
one day. Moreover, in the later hours, there was no significant 
increase in plasma melatonin levels, perhaps because of adap-
tive desensitization of pineal β-adrenoceptors to high levels 
of norepinephrine or because the peak capacity of the pineal 
gland to synthesize melatonin was reached.159 Like desipra-
mine, fluvoxamine also had a positive effect on melatonin 
after acute administration,160 and the same results were found 
for both acute and chronic administration of oxaprotiline, a 
serotonin-norepinephrine reuptake inhibitor.161 A positive 
effect was found also for mirtazapine162 and clomipramine,163 
but the latter was associated also with a normalization of 
pineal activity after long-term treatment. Here the increase 
in melatonin also seemed to be associated with an improve-
ment in emotional state. The monoamine oxidase inhibitors, 
tranylcypromine and pirlindole, the tetracyclic antidepres-
sant maprotiline, and the serotonin S2-receptor antagonist, 
mianserin, were compared with fluvoxamine, each given for 
3 weeks, but only the latter had an effect on melatonin.164 
Interestingly, total melatonin excretion was increased by 
desipramine, advancing onset, and by   fluvoxamine, delaying 
offset. The acrophase was also modulated, being delayed 
with fluvoxamine and advanced with desipramine. Similarly 
opposite effects in melatonin metabolism were seen whereby 
increased aMT6s levels followed desipramine and decreased 
levels followed   fluvoxamine. These studies confirm the 
hypothesis that the effect of desipramine is exerted mainly 
on melatonin synthesis, while fluvoxamine modulates its 
catabolism.165
In summary, antidepressants appear to modulate mela-
tonin via three main mechanisms: pineal β-adrenoceptor 
stimulation by elevated levels of norepinephrine in the syn-
aptic junction, though this effect seems susceptible to adap-
tive desensitization of receptors; modulation of melatonin 
catabolism; serotonergic stimulation of the suprachiasmatic 
nuclei by projections from the raphe nuclei which modulate 
the response of the suprachiasmatic nuclei to light signals 
from the retinohypothalamic tract. Antidepressants also may 
modulate melatonin by a direct effect on expression of the 
enzymes involved in its synthesis, and the increase in circulat-
ing serotonin by some antidepressants like monoamine oxi-
dase inhibitors and fluoxetine can be another mechanism.166,167 
Fewer studies have investigated the effects of selective sero-
tonin reuptake inhibitors on melatonin.  Fluoxetine increases 
melatonin levels after effective antidepressant treatment.156,168 
In contrast, paroxetine caused no alterations in melatonin in 
eight healthy   volunteers.169 Tan et al showed no significant 
differences with selective serotonin reuptake inhibitors, but 
it is noteworthy that they positively associated the amplitude 
of melatonin secretion and improvement in recovery from 
depression after fluoxetine treatment.170
Effects on circadian rhythm
Can antidepressants influence biological rhythms? This 
issue is summarized in Table 3. Some hints come from 
studies in rats which tested mainly the effects of activation 
of the serotonergic system on the suprachiasmatic nucleus. 
  Serotonergic agonists and selective serotonin reuptake 
inhibitors, like fluoxetine, seem to have both a photic (night-
time phase shifts) and nonphotic influence (daytime phase 
shifts and   night-time photic resetting attenuation). The first 
Table 2 Antidepressant effect on melatonin in healthy subjects
Name Antidepressant Treatment Plasma melatonin Urinary 6-sulphatoximelatonin
Cowen et al19 Desipramine Acute 
3 weeks
↑ 
=
Demisch et al160 Fluvoxamine Acute (once) ↑
Demisch et al164 Tranylcypromine 
Pirlindole 
Maprotiline 
Fluvoxamine
Baseline – 3 weeks 
” 
” 
”
= – =  
= – =  
= – =  
↑ – ↑
Franey et al159 Desipramine Acute ↑ ↑
Palazidou et al162 Mirtazapine Acute ↑
Palazidou et al161 (+)Oxaprotiline 
(-)Oxaprotiline
3 weeks 
3 weeks
↑ 
=
Skene et al165 Fluvoxamine 
Desipramine
Acute 
Acute
↑ 
= 
↓ 
↑
Markus et al163 Clomipramine Acute 
3 weeks
↑ 
=
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probably occurs through 5-HT(3) and 5-HT(2C) recep-
tor interactions, while the second seems related to direct 
modulation of clock genes, possibly through 5-HT(1A) 
receptors, ie, downregulation of Per1 and Ror-beta expres-
sion and upregulation of Rev-erb-alfa, correlated with 
daytime behavioral phase advance, while night-time photic 
resetting attenuation is associated with altered expression 
of Per1, Per2, and Ror-beta.171 A consistent phase advance 
in neuronal firing was showed in rat slices after treatment 
with fluoxetine and tryptophan.172
Effects on the HPA axis
Glucocorticoids exert their physiological action through GR. 
We know that impairment of the HPA axis is implicated in 
the etiology of depression, and because there is evidence that 
antidepressants may have an effect on these receptors, we 
believe that this is part of their therapeutic action (Table 4). 
Several studies have demonstrated that GR is upregulated by 
antidepressants; rats treated with desipramine or   imipramine 
showed an increase in hippocampal and hypothalamic GR 
mRNA levels,173 and in vitro antidepressant   treatment for 
24 hours increased GR expression, promoted GR nuclear 
translocation, and enhanced GR function in mouse fibro-
blasts.114,174 Similar results were found for animal neuronal 
cells treated with either selective serotonin reuptake inhibitors 
or tricyclic antidepressants.175 Such treatment also showed 
modulation of GR function in peripheral red blood cells.176 
Furthermore, recent studies have shown an effect of antide-
pressants on circulating levels of corticosteroids. Fluoxetine 
effectively reduced cortisol levels when given to alcohol-
treated rats.177 Also, perinatal exposure to maternal selective 
serotonin reuptake inhibitors can induce a lower basal cortisol 
level in the newborn.178 Long-term mirtazapine treatment 
decreases levels of cortisol and dehydroepiandrosterone, an 
androgen secreted by the adrenal gland, a decrease in which 
can be used to assess HPA axis function,179 and there seems 
to be a relationship between dehydroepiandrosterone reduc-
tion and the therapeutic effect of an antidepressant.180,181 Also, 
one study found that restoring of HPA axis hyperactivity 
in 194 depressed patients was associated with remission, 
and, moreover, the integrity of negative feedback in the 
HPA axis, as assessed by DST, predicted the response to 
Table 3 Antidepressant effects on circadian rhythm
Name Antidepressant Treatment Neuroendocrine alterations
Cuesta et al171 Fluoxetine Rats Clock gene expression modulation 
(Per1, Per2, Ror-beta)
Sprouse et al172 Fluoxetine + tryptophan Rat slices Phase advances in neuron firing
Table 4 Antidepressant effects on HPA axis
Name Antidepressant Treatment Neuroendocrine alterations
Peiffer et al173 Desipramine, 
imipramine
Rats ↑ hippocampal and hypothalamus GR mRNA
Pariante et al114 
Pariante and Miller69
Desipramine 
Dexamethasone + 
amitriptyline, clomipramine,  
paroxetine, citalopram
In vitro mouse fibroblasts cells  
↑ GR expression, promote GR nuclear  
translocation and enhance GR function
Okugawa et al175 Dexamethasone + desipramine  
amitriptyline 
Desipramine, amitriptyline 
mianserin, paroxetine 
sulpiride
Rat hippocampal neurons ↑ GR binding 
 
↑ GR mRNA
Carvalho et al176 Clomipramine, 
amytriptyline, sertraline,  
paroxetine, venlafaxine
Peripheral red blood cells of healthy  
subjects
↓ GR function
Hu et al177 Fluoxetine Alcohol-treated rats ↓ cortisol levels
Oberlander et al178 Serotonin Newborn after prenatal exposure ↓ basal cortisol level
Schule et al180 Mirtazapine Depressed patients ↓ cortisol 
↓ dehydroepiandrosterone sulfate
Paslakis et al181 Mirtazapine 
venlafaxine
Depressed patients ↓ dehydroepiandrosterone sulfate
Abbreviations: HPA, hypothalamo-pituitary-adrenal; GR, glucocorticoid receptor.
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an   antidepressant.182 In accordance with this, a recent study 
found that resistance to treatment was associated with an 
abnormal HPA axis negative feedback response, as assessed 
by prednisolone activation of the GR and mineralocorticoid 
receptor.183 Some controversial results come from two stud-
ies184,185 measuring the effects of venlafaxine or sertraline 
on cortisol and showing no effect or even increased levels; 
however, these studies are limited by their small sample sizes, 
while previous studies refer to much bigger sample sizes, and 
are thus more reliable.
Effects on the immune system
There are many studies showing a direct effect of antide-
pressants on inflammatory cytokines. Results come from 
studies in cells, animals, and humans (Table 5). Two stud-
ies conducted in animal glial cells showed a decrease in 
proinflammatory cytokines after exposure to an antidepres-
sant and stimulation with interferon gamma, fluvoxamine, 
reboxetine, and imipramine, along with decreased levels 
of nitric oxide186 when treated with lipopolysaccharide, 
while amitriptyline and nortriptyline decreased levels of 
IL-1 and tumor necrosis factor alpha.187 Another study in 
encephalitogenic T cell clones, splenocytes, and peritoneal 
macrophages from rats showed that venlafaxine induced a 
decrease in generation of IL-12, tumor necrosis factor alpha, 
and interferon gamma.188 Moreover, experiments conducted 
in stimulated peripheral white blood cells are in accordance 
with these findings, ie, imipramine, mianserin, clomip-
ramine, sertraline, and   citalopram reduced proinflammatory 
cytokine levels and increased anti-inflammatory cytokine 
levels.189–191 Accordingly, whole blood from healthy controls 
and treatment-resistant patients incubated with lipopolysac-
charide and treated with antidepressants showed markedly 
reduced levels of proinflammatory cytokines compared with 
untreated blood.192,193 Finally, studies in depressed patients 
confirm the hypothesis that antidepressants have an anti-
inflammatory effect. In patients with major depression, long-
term treatment with selective serotonin reuptake inhibitors 
decreased tumor necrosis factor alpha, C-reactive protein, 
and leukocyte levels similar to those found in controls.2,98 
In one study, 48 depressed patients received either bupro-
pion, mirtazapine, citalopram, paroxetine, or venlafaxine 
for 6 weeks, and again there was a significant decrease in 
proinflammatory cytokines.195 Furthermore, desipramine and 
fluoxetine seem to have an inhibitory effect on indoleamine-
2,3-dioxygenase activity.196 More details on the effects of 
antidepressants on the immune system have been reviewed 
by Janssen et al.197
Agomelatine
Promising results have been reported for agomelatine, a new 
antidepressant with both serotonergic and melatonergic activ-
ity. Agomelatine inhibits the serotonergic system through its 
5HT-2C receptor antagonist properties, and stimulates the 
melatonergic system via melatonin receptor agonist binding. 
Serotonergic blockade leads to enhancement of the frontocorti-
cal adrenergic and dopaminergic pathways responsible for its 
antidepressant activity, and melatonergic stimulation accounts 
Table 5 Antidepressant effects on immune system
Name Antidepressant Type Neuroendocrine alterations
Hashioka et al186 Fluvoxamine, reboxetin, imipramine Murine glia cells ↓ NO levels after iFNγ stimulation
Obuchowicz et al187 Amitriptyline, nortriptyline Rat glia cells ↓ iL1 and TNFα after LPS 
stimulation
vollmar et al188 venlafaxine Rat encephalitogenic T cell clones,  
splenocytes, peritoneal macrophages
↓ iL12, TNFα, and iFNγ
Taler et al189 
Xia et al190 
Szuster-Ciesielska et al191
imipramine, mianserin, clomipramine,  
sertraline and citalopram
Human peripheral white blood cells ↓ proinflammatory cytokines 
↑ anti-inflammatory cytokines
Kubera et al193 Imipramine, venlafaxine, fluoxetine Healthy human whole blood 
Treatment resistant
↓ iL-10
Tuglu et al98 Sertraline, citalopram, fluoxetine,  
fluvoxamine, paroxetine
Depressed patients ↓ TNFα, CRP and leukocyte count
Kim et al194 Bupropion, mirtazapine, citalopram,  
paroxetine, venlafaxine
Depressed patients ↓ iL-6 and TGF-beta1
Sutcigil et al195 Sertraline Depressed patients ↓ iL-12 
↑ iL-4 and TGF-beta1
Walsh and Daya196 Desipramine and fluoxetine Rats ↓ iDO activity
Abbreviations: CRP, C-reactive protein; iDO, indoleamine-2,3-dioxygenase; iL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor; iFNγ, interferon 
gamma; LPS, lipopolysaccharide.
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for its chronobiotic re-entrainment features.198–200 Studies in 
rats,201,202 healthy subjects203,204 and depressed patients205–207 had 
interesting findings with regard to the capacity of agomelatine 
to re-entrain abnormal circadian rhythms. Moreover, it has a 
better side effect profile,208 in particular concerning sexual 
impairment in comparison with other antidepressants,209 and 
low discontinuation symptoms after withdrawal compared with 
the selective serotonin reuptake inhibitor, paroxetine.210
Conclusion
Major depression is a multifactorial and complex disorder, 
with social, psychological, and biological components. In 
this review, we have focused mainly on the neuroendocrine 
basis of these abnormalities. It is clear that melatonin, the 
HPA axis, immune system, and circadian rhythms are pro-
foundly altered in depressed patients compared with healthy 
subjects. Moreover, we show how all those systems are 
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interconnected (Figure 4). Melatonin, in addition to being 
a well known circadian rhythm modulator, has been shown 
to regulate immune system activity, having proinflamma-
tory and anti-inflammatory actions, to downregulate the 
HPA axis and cortisol secretion, and to modulate excessive 
elevations in corticosteroids. Glucocorticoids, in addition to 
their established immunosuppressive action, seem to have 
an upregulatory effect on melatonin synthesis. Cytokines, 
on the other hand, have been shown to inhibit GR function, 
and inflammation has shown a negative effect on melatonin 
synthesis. These interconnections may play an important 
role in the pathogenesis of depression. The immune system 
and the HPA axis, along with elevation of corticosteroids, 
act as important biological defense systems under conditions 
of stress. It seems that prolonged and chronic activation of 
these mechanisms leads to neurotoxic alterations in the brain 
that may eventually trigger depression; also, a genetic pre-
disposition to this is shown, ie, polymorphism in melatonin 
promoter enzymes. We tried to determine in the literature 
if antidepressants could play a role in these neuroendocrine 
alterations. We identified that these agents work separately on 
each of these interconnected systems. In fact, they have anti-
inflammatory actions, stimulate melatonin synthesis, restore 
negative glucocorticoid feedback by upregulation of GR, and 
modulate circadian rhythm. It is possible then that all these 
modifications influence each other synergistically. Inhibition 
of inflammation itself may first restore melatonin levels, 
having the least anti-inflammatory properties, and, secondly, 
benefit negative feedback in the HPA axis.   Restoration of 
GR may positively influence the anti-inflammatory action 
of glucocorticoids, their stimulation of melatonin secretion 
by the pineal gland, and perhaps their influence on negative 
feedback by adrenal gland clock genes. An increase in mela-
tonin on the other hand may influence the other systems. It 
seems that antidepressants, in addition to increasing primary 
monoamine levels in the synaptic cleft, work at different 
neuroendocrine levels, each closely related to others. Further 
research will help to clarify the complex mechanisms under-
lying depression and the actions of antidepressants upon all 
the neuroendocrine systems.
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